Second quarter 2023 results
Second quarter 2023 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.
14:30 -16:00 CET | 8:30am – 10am EST
Featuring

Paul Hudson
Chief Executive Officer

Jean-Baptiste de Chatillon
Chief Financial Officer

Bill Sibold
Specialty Care

Olivier Charmeil
General Medicines

Dietmar Berger
Global Head of R&D ad interim

Thomas Triomphe
Vaccines

Julie van Ongevalle
Consumer Healthcare

Roy Papatheodorou
General Counsel
Highlights


We delivered another solid quarter of growth and are excited by the momentum of our R&D pipeline, with a strong flow of positive readouts and regulatory achievements that match our best-in-class ambitions.

Paul Hudson
Chief Executive Officer